LGBT Cancer Project

Therapeutic Areas: Oncology | Family Medicine

Cancer/Tumors Clinical Trials

A listing of Cancer/Tumors medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Incyte Corporation
Whittier California

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Florida

Jupiter Medical Center
Jupiter Florida 33458

Procurement of Human Biospecimens for Research

Jupiter Medical Center
Jupiter Florida 33458

Procurement of Human Biospecimens for Research

Georgia

Memorial University Medical Center
Savannah Georgia 31404

Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors

Memorial University Medical Center
Savannah Georgia 31404

National Oncologic PET Registry (NOPR)

Michigan

Mirati Research Site
Detroit Michigan 48202

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

New Jersey

Mirati Research Site
Hackensack New Jersey

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

New York

Mirati Research Site
Bronx New York 10461

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

Oregon

Incyte Corporation
Portland Oregon

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Pennsylvania

Incyte Corporation
Bethlehem Pennsylvania

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Texas

Mirati Research Site
Dallas Texas 75201

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

Virginia

Incyte Corporation
Fairfax Virginia

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Mirati Research Site
Fairfax Virginia 22031

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Washington

Mirati Research Site
Seattle Washington 98109

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer